Navigation Links
Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer
Date:7/17/2009

M&A, restructurings and divestitures.

The Board of Directors offered, and Mr. Karkus accepted, the position of CEO at a salary of $750,000 (plus customary employee benefits). The Board also offered, and Mr. Cuddihy accepted, the position of COO at a base salary of $275,000 (plus customary employee benefits) as well as an annual grant of $50,000 in the Company's common stock. Mr. Karkus was formerly the interim CEO and Mr. Cuddihy was formerly a financial consultant to the Company while the Board was reviewing the Company's operations.

The Company does not have a currently effective equity compensation plan. Accordingly, neither Mr. Karkus nor the current board members may receive stock options or stock grants unless and until such time as an equity incentive plan is adopted by shareholders.

Recent resignations of senior executives and further reductions of head count have reduced the Company's overall payroll expense by approximately $1.75 million per year, compared to 2008 levels, even after the hiring of Mr. Karkus and Mr. Cuddihy.

The Compensation Committee of the Board of Directors was assisted by Buck Consultants in formulating the CEO compensation arrangement and has been engaged as the compensation consultant to the Compensation Committee.

Buck Consultants, a wholly owned subsidiary of ACS, began in 1916 and has grown into a diversified firm that provides consulting services to both public and private entities, large and small, covering the entire employee benefit, compensation and broader human resource management fields. Today, Buck is one of the leading benefit and compensation consulting and actuarial services firms in the world with more than 1,500 professionals worldwide.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: '/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Ted Karkus Appointed Interim Chief Executive Officer Of The Quigley Corporation
2. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
3. Ted Karkus Admits to Financial Relationship With Dr. Richard A. Rosenbloom; Demonstrates Pattern of Improper Influence, Unethical Behavior, Falsification and Distortion; Company Questions What Else Karkus May Be Hiding From Shareholders
4. Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
5. Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Companys Latest Announcement
6. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
7. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
8. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
9. The Mount Sinai Medical Center Named to "Honor Roll" in U.S. News's 2009-10 Edition of America's Best Hospitals
10. National Jewish Health Named Top Respiratory Hospital for 12th Consecutive Year
11. St. Alexius Medical Center Named to Americas Best Hospitals Rankings

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2009)... Hall, president and chief executive officer of th...he following statement regarding the inclusion of ...annual wellness for Medicare beneficiaries in &quo...uot; that was introduced last night: , ...09 -- Eric J. Hall, president and chief executive ...
(Date:11/20/2009)...0 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals...hareholders will be held on Monday, December 21, 2...roval of two special resolutions. The first specia...of all or substantially all of the assets of NUCRY... asset purchase agreement dated November 10, 2009 ...
(Date:11/20/2009)...s and Congressmen in Competitive Re-election Battl... , Washington, DC (Vocus)...ning for re-election next year in races deemed to ... come to regret voting for House Speaker Nancy Pel...ing Zogby International/ O’Leary Report pol...
(Date:11/20/2009)...November 20 Cardio Vascu...SLMEDICAL.COM , a leading,developer of advanced ca...hat,the company,s Board of Directors has decided t...nd the Far East for its proprietary next-generatio...asty (PCTA) procedures. , Cardio Vascular...
(Date:11/20/2009)...ovember 20 in the Journal of the National Cancer ...es that often appear in news coverage of cancer re...he media and journals to help alleviate the proble...loshin, M.D., M.S., of Center for Medicine and the...y and Clinical Practice in New Hampshire, and Barn...
Breaking Medicine News(10 mins):Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2
...re Holdings,Inc. (Nasdaq: LNCR ) today announced ...nd Exchange Commission (the "SEC") a resale shelf ...08 on Form S-3 pursuant to the terms,of a registra...debentures due 2037 - Series A and $275 million,pr...
...on of KV,s Securities until February 15, ... KV Pharmaceutical Company,(NYSE: KVa/KVb) a fully...develops, manufactures, acquires and markets techn...request for a,trading extension through February 1...
...er in Next Generation Health Management ...ec. 28 It is a true win-win,situation. Crown Equi...rove,the health and productivity of its workforce....low health risk category,- an improvement of 12 pe...
...of restricted calorie intake for diabetics wanting...8 (HealthDay News) -- For the first time, the Amer...pport of low-carbohydrate diets for people with di...ractice recommendations. , The recommendations are...
...stCall/ - Transition Therapeutics Inc.,("Transitio...pleased to,announce that Mr. Carl Damiani has been... Since joining Transition in 2003, Mr. Damiani has...ding licensing and intellectual property strategie...
...(NYSE: MYL ),today announced that Mylan Pharmaceu....S. Food and Drug Administration (FDA) for its Abb...e Hydrochloride Tablets (OTC), 5 mg,and 10 mg., C...ng Sept. 30, 2007., This product will be shipped ...
Other Medicine News:Health News:Lincare Holdings Inc. Reports Intention to File Shelf Registration Statement 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 3Health News:Improving Employee Health While Reducing Costs - A Serious Business Strategy 2Health News:Improving Employee Health While Reducing Costs - A Serious Business Strategy 3Health News: Diabetes Group Backs Low-Carb Diets 2Health News:Transition Therapeutics Announces Appointment of Vice-President of Business Development 2
(Date:11/19/2009)...Newswire/ -- As the seasons change, another season...on preparing yourself. ,, Listen to this report...: ,, http://inr.mediaseed.tv/oneClip_C/?feed...nk is a division of The NewsMarket. Registered jo...and photos at http://www.thenewsmarket.com . ,...
(Date:11/19/2009)... 19 Mach 7 Technologies, a globa...age management solutions, and QStar Technologies h...- neutral archive solution through their common US...national leader in providing digital image distrib...try. Under the agreement, Data Distributing will ...
(Date:11/19/2009)...19 Impliant, Inc., a developer of ...pinal fusion surgery, announced today that it has ...as the Vice President of Clinical and Regulatory A...gi-bin/prnh/20080527/NETU060LOGO ) ,, Mr. Rol...rience in the spinal and medical device field to I...
Breaking Medicine Technology:Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 2Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 3Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 4Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 3Stories we tell about national trauma reflect our psychological well being 52964 1Stories we tell about national trauma reflect our psychological well being 52964 2Stories we tell about national trauma reflect our psychological well being 52964 3Microbes and their hosts exploring the complexity of symbiosis in DNA and cell biology 9396 1Microbes and their hosts exploring the complexity of symbiosis in DNA and cell biology 9396 2Wildfires set to increase 50 percent by 2050 9392 1Wildfires set to increase 50 percent by 2050 9392 2
... - INNOVIVE Pharmaceuticals,Inc. (OTCBB:IVPH) tod... INNO-406, a potent oral dual Bcr-Abl and Lyn-kina...tolerant chronic,myelogenous leukemia, will be pre...arch Annual Meeting. The meeting takes place April...in Los Angeles,California., Information related t...
...n Valopicitabine Combined,with an Investigational ...07 /PRNewswire-FirstCall/ --,Idenix Pharmaceutical... studies of the novel combination of valopicitabin...s(R)) in both treatment-naive,and treatment- exper...n of the hepatitis C virus (HCV). These data, as w...
Other Medicine Technology:Innovive Pharmaceuticals Announces Additional Data Presentations at,American Association for Cancer Research Annual Meeting 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 5Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 6Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 7
OSR Phenytoin Assay
Digoxin II
Emit 2000 (Convenience Pack) Digoxin Assay
Revised Drug Calibrator
Medicine Products: